Bovine spongiform encephalopathy infection alters endogenous retrovirus expression in distinct brain regions of cynomolgus macaques (Macaca fascicularis) by Greenwood, Alex D et al.
RESEARCH ARTICLE Open Access
Bovine spongiform encephalopathy infection
alters endogenous retrovirus expression in
distinct brain regions of cynomolgus
macaques (Macaca fascicularis)
Alex D Greenwood
1†, Michelle Vincendeau
2,5†, Ann-Christin Schmädicke
3, Judith Montag
3,6, Wolfgang Seifarth
4
and Dirk Motzkus
3*
Abstract
Background: Prion diseases such as bovine spongiform encephalopathies (BSE) are transmissible
neurodegenerative diseases which are presumably caused by an infectious conformational isoform of the cellular
prion protein. Previous work has provided evidence that in murine prion disease the endogenous retrovirus (ERV)
expression is altered in the brain. To determine if prion-induced changes in ERV expression are a general
phenomenon we used a non-human primate model for prion disease.
Results: Cynomolgus macaques (Macaca fasicularis) were infected intracerebrally with BSE-positive brain stem
material from cattle and allowed to develop prion disease. Brain tissue from the basis pontis and vermis cerebelli of
the six animals and the same regions from four healthy controls were subjected to ERV expression profiling using a
retrovirus-specific microarray and quantitative real-time PCR. We could show that Class I gammaretroviruses HERV-
E4-1, ERV-9, and MacERV-4 increase expression in BSE-infected macaques. In a second approach, we analysed ERV-
K-(HML-2) RNA and protein expression in extracts from the same cynomolgus macaques. Here we found a
significant downregulation of both, the macaque ERV-K-(HML-2) Gag protein and RNA in the frontal/parietal cortex
of BSE-infected macaques.
Conclusions: We provide evidence that dysregulation of ERVs in response to BSE-infection can be detected on
both, the RNA and the protein level. To our knowledge, this is the first report on the differential expression of ERV-
derived structural proteins in prion disorders. Our findings suggest that endogenous retroviruses may induce or
exacerbate the pathological consequences of prion-associated neurodegeneration.
Background
Prion diseases are fatal transmissible neurodegenerative
diseases that include Creutzfeldt-Jakob Disease (CJD) in
humans and bovine spongiform encephalopathy (BSE)
in cattle [1-4]. A key observation in the development of
prion diseases is the accumulation of the abnormal iso-
form (PrP
Sc) of the host encoded prion protein (PrP
C)
in the brain of affected individuals [5,6]. As a result,
neuronal loss and astrogliosis lead to the clinical
symptoms associated with prion diseases such as ataxia
and dementia. The mechanism by which PrP
C is con-
verted to PrP
Sc is not well understood. As a result, sev-
eral researchers have hypothesized that host-derived
nucleic acids or other non-PrP molecules contribute to
the propagation of prions [7-10]. In search of these
unknown factors, multiple studies in mice and humans
have examined host gene expression response to prion-
infection revealing multiple biochemical pathways that
are disturbed. These altered pathways may contribute to
prion disease pathology [11-22] though most studies
have yielded conflicting results among tissue types,
methods, and cell lines used [23].
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consequence of prion infection in both, cell lines and
tissue samples from humans and mice, are endogenous
retroviruses (ERVs) [24-28]. ERVs are the remnants of
germline infection by relatives of exogenous retroviruses
such as murine leukemia virus (MLV) and mouse mam-
mary tumor viruses (MMTV) [29]. Endogenization is a
frequent event as the genomes of all mammals studied
are composed of 8-11% retrovirus-like sequences. They
are not only passive components of the genome or
“Junk DNA”,b u tc a na l s op l a yi m p o r t a n tf u n c t i o n a l
roles. For example the ERV-derived proteins syncytin-1
and -2 are essential for trophoblast differentiation in
placental development [30-33]. The long terminal
repeats (LTRs), which control retroviral gene expression
can also change host RNA levels [29]. Additionally, the
ERV-expression pattern has been shown to be altered in
a murine cell culture model for prion infection [25] and
in the cerebrospinal fluid (CSF) of sporadic CJD patients
[28]. The PrP and ERV expression in some immune-
stimulated mouse tissues also appear to be linked [34].
Infections of mice with ecotropic neurovirulent retro-
viruses can also be associated with prion-like disorders.
The MLV strains Cas-Br-E, Friend MLV Fr98 and the
ts-1 mutant of MoMLV cause neuropathology that is
similar to prion-induced spongiosis [35-37]. Interest-
ingly, the prion gene is totally dispensable in the patho-
genesis and tropism of Cas-Br-E [36]. This lead to the
conclusion that retroviral-induced neurodegeneration
may act in a common pathway but downstream of prion
infection.
To date, the expression of endogenous retroviruses in
human CJD has only been analysed in patients’ CSF
samples [28]. ERV profiling in brain tissue from human
CJD has not been performed. A systematic analysis in a
controlled experimental non-human primate model for
prion disease provides the unique opportunity for exam-
ining the expression of ERVs in response to infectious
prions in the primate brain. Cynomolgus macaques are
an excellent model for human acquired prion disease.
TSEs can be transmitted to Macaca fascicularis leading
to disease that is comparable to humans, including
preclinical incubation time, clinical symptoms and
pathophysiology [38]. For ERV expression analysis, a
microarray system for the detection of human endogen-
ous retroviral expression has been successfully applied
to genomic DNA and RNA derived from rhesus maca-
que tissues (Macaca mulatta) [39] or brain tissue from
barbary macaques (Macaca sylvanus) [40].
The aim of our study was to assess the putative dysre-
gulation of endogenous retroviruses on the transcrip-
tional and protein level linked to prion pathology. For
this reason we analyzed three defined brain regions, ver-
mis cerebelli, basis pontis and the frontal/parietal cortex.
The samples from the infected macaques were
compared to samples from the same brain regions of
non-infected control animals. Changes in gene expres-
sion were examined using a retrovirus-specific microar-
ray [40] and quantitative real-time PCR (QPCR).
Western blot analysis with an HERV-K-(HML-2) Gag
specific antiserum was used to investigate changes at
the protein level.
Methods
Tissues and RNA extraction
Cynomolgus macaques (Macaca fascicularis)w e r ep u r -
chased from the Centre de Recherche en Primatologie,
Mauritius and maintained in social groups of six mon-
keys housed in a microbiological containment level
BSB3 facility. Ethics approval for the study was issued
by the Lower Saxony Ministry for consumer protection
and food safety (509.42502/08/07.98). Animal experi-
mentation was performed in accordance with section 8
of the German Animal Protection Law in compliance
with EC Directive 86/609. It should be mentioned that
the diet and housing of the used experimental and the
control animals were not identical. This may well have
contributed to the inter-individual variations among the
animals. Six cynomolgus macaques were intracerebrally
inoculated with 50 mg bovine BSE-positive brain stem
material derived from an EU-standard inoculum. Inocu-
lation was performed by slow injection of 250 μlo fa
20% BSE brain homogenate (w/v) diluted in sucrose into
the right hemisphere through the dura mater into the
caudo-putamen. The preclinical incubation time was on
average 1,100 days. Animals were sacrificed, and the
brains were dorso-ventrally sliced and snap-frozen on
dry-ice plates. Brain material from age-and sex-matched
non-infected cynomolgus macaques was obtained from
Covance Laboratory Münster GmbH and processed in
an equivalent manner. Three different brain regions
(vermis cerebelli, basis pontis, frontal/parietal cortex)
were macroscopically identified on the frozen brain
s l i c e s ,i s o l a t e dv i aab o r ed e v i c ea n dg r o u n dt op o w d e r
under liquid nitrogen (for extraction of RNA) or homo-
genized (for extraction of protein).
Total RNA (RNA > 200 bases) was isolated from each
sample using a mirVANA kit (Ambion). To remove
genomic DNA, all RNA samples were treated with 1 U/
μg RQ1 RNase-free DNase I (Promega). Subsequently,
25 ng of each RNA preparation was tested by PCR with
retroviral mixed oligo primers (MOP) as described pre-
viously [41] omitting the reverse transcription step.
Only RNA preparations negative for amplification pro-
ducts were used for reverse transcription and MOP
multiplex PCR. Samples tested positive were treated
again with DNase I until the MOP multiplex control
PCR were negative. This precaution was taken to ensure
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pletely DNA-free.
Reverse transcription, PCR and microarray analysis
Reverse transcription of RNA was performed using 1 μg
total RNA with Superscript II (Roche Diagnostics)
according to the manufacturer’s protocol. Reverse tran-
scriptions were followed by an RNase H digestion step
(Promega). Syntheses of hybridization probes, labelling
of MOP PCR products, preparation, hybridization and
post-processing of retrovirus-specific DNA microarrays
were performed as previously described [41,42]. The
exception was that PCRs were performed with KAPA2G
Robust DNA Polymerase (Peqlab Biotechnologie
GmbH) which was found to improve the microarray
results substantially in terms of reproducibility and sig-
nal intensity (data not shown).
Hybridized microarrays were scanned using an Affy-
metrix GMS 418 scanner (laser power setting, 100%;
gain setting, 50%), and the resulting images (16-bit TIFF
files) were subjected to densitometric analysis using
ImaGene 4.0 software (BioDiscovery Inc.). To discrimi-
nate positive signals from background, a cut-off value of
1,200 relative fluorescence intensity units was used that
corresponded to twofold overall background intensity
value of the microarray. To account for the influence of
RNA quality, HERV signals were normalized to the
fluorescence intensity of the hypoxanthine-guanine
phosphoribosyltransferase (HPRT) transcript as a house-
keeping gene showing the most consistent transcript
levels on the microarray. This was confirmed by densi-
tometric analysis which demonstrated that there was no
statistically significant difference in HPRT expression
difference between infected and uninfected animals
(data not shown). Thus, microarray-based relative HERV
transcript levels were expressed as a ratio of HERV to
HPRT. Microarray data were submitted to Gene Expres-
sion Omnibus (GEO: GSE29818).
QPCR
Primers used for quantitative real time PCR (QPCR)
were HERV-E: E4-1 (forward, 5’-GGTGTCACTACTC
AATACAC-3’; reverse, 5’-GCAGCCTAGGTCTCTGG-
3’), MacERV-4 (forward, 5’-ATGTAGCTGCCGCTATA-
GAG-3’;r e v e r s e ,5 ’-GCTATTTGTAGTCCGGCTGC-3’)
and ERV-K (HML-2) gag (forward, 5’- TATGATTGG-
GAGATTCTGGCA-3’;r e v e r s e ,5 ’-GCAGCCCTAT
TTCTTCGGAC-3’). The HERV-E, and MacERV-4 pri-
mers were previously shown to work on barbary maca-
ques [40]. QPCR was performed with the Roche
LightCycler480 System, using LC-480 SybrGreen PCR
mix and a standard LightCycler protocol (Roche Diag-
nostics). Amplifications were performed using a 10 min
denaturation step at 95°C, followed by 45 cycles of 10 sec
at 95°C, 5 sec at 60°C, and 10 sec at 72°C. RNA-Polymer-
ase II-transcripts (RPII) were analyzed as a standard,
using published primers [43]. For quantification of ERV-
K (HML-2) a 7500 Real Time PCR System (Applied Bio-
system) was used. Reaction was performed after 10 min
denaturation with 45 cycles between 95°C for 15 sec and
58°C for 45 sec using Power SybrGreen PCR Mastermix
(Applied Biosystems) with 2.5 ng RNA equivalent
amount and 400 nM of each primer per reaction. The
relative expression ratio was calculated as described [44].
Melting curve analysis and gel electrophoresis of amplifi-
cation products was performed to verify that artefact pro-
ducts or primer dimers were not responsible for the
signals obtained (see Additional file 1: Figure S3).
Western blot analysis
Frontal/parietal cortex samples were homogenized in
sample buffer (62.5 mM Tris/HCl, pH 6.8, 62.5 mM
Imidazol, pH 6.8, 10% SDS, 0.01% bromphenolblue,
12.5% glycerol, 2.5% beta-mercaptoethanol) at 20% (w/v)
and stored at -80°C prior to use. Extracts were spun for
2 min at 7,000 × g and the supernatant was diluted 1:1
in LDS sample buffer (Invitrogen). 10% Glycerol (v/v)
was added and samples were incubated for 5 min at 95°
C and cooled on ice. For immunoblotting, 10 μlo f
supernatant was separated on a 12% Bis-Tris polyacryla-
mide gel in MOPS-SDS running buffer (NuPAGE, Invi-
trogen) together with a molecular weight marker
(Spectra Multicolor Broad Range Protein Ladder, Fer-
mentas) for 150 min at 30 mA. The gel was blotted
onto a PVDF membrane (Immobilon-P transfer mem-
brane 0.45 μm, Millipore) in transfer buffer (NuPAGE,
Invitrogen) for 70 min at 135 mA. Prion infectivity of
the blot was inactivated by incubation in 4 M Guanidi-
nium-Thiocyanate (Roth) for 30 min at room tempera-
ture with slow agitation. The PVDF was washed in TBS
and unspecific binding was blocked with 0.2% Casein
(I-Block, Applied Biosystems) for 30 min at room tem-
perature. As primary antibody, a polyclonal antiserum
(K2548) that was raised against full length HERV-K-
(HML-2) Gag [45] was used at a dilution of 10
-2.T h i s
antiserum was generated as described for serum 6897
[45]. A pre-immune serum derived from the same ani-
mal was used as a negative control. As a loading control,
a b-actin antibody (mAbcam 8224) was used at a dilu-
tion of 10
-3. Antibody incubation was performed over-
night at 4°C in TBS/0.02% Casein. Detection was carried
out using anti-rabbit IgG-AP (A9919, Sigma-Aldrich) at
ad i l u t i o no f1 0
-5 in TBS/0.02% Casein for 1 h at room
temperature with gentle agitation. Bands were visualized
with NBT/BCIP substrate (Moss Inc.) for 10 min. The
reaction was stopped by addition of ddH2Oa n d
scanned. Densitometric analysis was performed with the
program Image J 1.37 v.
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Data analysis was performed using GraphPad Prism 5.0.
Significance was calculated using unpaired student
t-test. The corresponding results are indicated in the
figures (***, p < 0.001; **, p < 0.01; *, p < 0.05).
Results
ERV expression profiling in two distinct brain regions
of cynomolgus macaques
We investigated whether the expression of endogenous
retroviruses was influenced by the infection with prions.
RNA was prepared from brain tissue of BSE-infected
and non-infected macaques at an advanced stage of
prion disease and subjected to reverse transcription with
random hexamer primers. Prior to cDNA syntheses, the
DNA-free status of each RNA sample was confirmed to
prevent interference from DNA copies of ERVs with the
microarray probes. It should be noted that the microar-
ray detects HERV groups and not individual HERVs.
Thus, signals arising from a HERV group do not neces-
sarily identify specific elements responsible for the
signal.
Initially we investigated the general expression, or core
profile, of ERVs derived from four non-infected cyno-
molgus macaques in two distinct brain regions, the basis
pontis and the vermis cerebelli ( F i g u r e1 ,f o raf u l lp r o -
file also see Additional file 1). The vast majority of the
human derived oligonucleotides on the microarray
cross-hybridized with macaque ERVs as has been
observed for Old World Monkeys in general [39]. ERV
profiling revealed high expression of class I gammaretro-
viruses HERV-E (E4-1, Seq32), HERV-F (HERV-Fb),
HERV-W, ERV9 (ERV9, Seq59), class II betaretroviruses
HERV-K-(HML-3: Seq26, Seq34, HML-3), HERV-K-
(HML-10): (HERV-KC4) and macaque specific ERVs
(MacERV-1, -2, -3, and -5). Among the animals we
detected inter-individual differences in the respective
expression pattern. Such differences have also been
reported for human studies [46], likely as a result from
the non-inbred genetic background of the tested indivi-
duals. However, the respective profiles of basis pontis
and vermis cerebelli regions were comparable among the
macaques.
Comparison of the derived ERV-expression profile in
macaques to that of healthy human brain samples [46]
revealed a partial overlap of the expressed ERVs
including HERV-E4-1, ERV9, Seq59 and HERV-KC4.
In contrast, HML-3 elements Seq26, Seq34 and Seq43,
that were not or only barely detectable in human
prefrontal cortex [46] were highly expressed in basis
pontis of macaques. Our results are consistent with
previous studies on both DNA and RNA from other
non-human primate species that showed both gener-
ally conserved presence and expression patterns for
several ERVs and additional species specific patterns
[39,40].
Differential expression of ERVs in BSE-infected macaques
Next we used the retrovirus-specific microarray to
compare the ERV-expression patterns of BSE-infected
with that of non-infected macaques. Quantitative com-
parison in two different brain regions revealed statisti-
cally significant differences between BSE-infected and
non-infected macaques (Figure 2). In the infected
animals pathogenic prion protein (PrP
Sc) was detected
in the vermis cerebelli and basis pontis as confirmed by
Western blot analysis (data not shown). A detailed
description of the distribution of macaque-adapted
BSE will be reported elsewhere. Increased expression
in BSE-affected macaques was detected for class I ele-
ments ERV-E4-1, the macaque specific MacERV-4 and
the ERV-9 elements Seq60, ERV9, Seq59. It should be
noted that, although statistically significant, upregula-
tion of MacERV-4 seemed to be mainly driven by out-
liers, as compared to the robust increase of expression
in E4-1 and ERV-9 indicating that for some affected
ERVs, there is interidividual variability in response to
prions. However, upregulation of these endogenous
retroviruses was detected in both, basis pontis and
vermis cerebellis.
Class II element ERV-K-(HML-3) Seq43 was statisti-
cally significant by microarray but also driven by outliers
(Additional file 1: Figure S2). None of the Class III
HERV-L related elements showed a consistent change in
expression. This was not surprising as they are related
to foamy viruses which do not cause any known patho-
logical effects as exogenous viruses and are widespread
in the genome of mammals indicating they have been
endogenized for tens of millions of years. No other
changes in ERV expression reached statistical signifi-
cance for either brain region.
Figure 1 Core ERV expression profile of macaque brain regions
basis pontis and vermis cerebelli. Fluorescence signal intensities of
ERV-specific microarray spots from four (1-4) non-infected
individuals are shown as false colour images. Individual ERV names
have been described earlier [42].
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macaques by QPCR
The retrovirus-specific microarray is a powerful tool for
the comprehensive expression analysis and comparison
of multiple ERVs in one single experiment. However,
the approach cannot differentiate between individual
group members of the tested ERVs. Consequently the
specificity of hybridization data can be increased by the
use of assays designed for the quantification of defined
transcripts in a given sample. To confirm the microarray
results for HERV-E4-1 and MacERV-4 specific PCR pri-
mers were designed. To confirm the specificity of the
chosen oligonucleotides the generated PCR products
were checked for specific products of the correct size
after amplification from cynomolgus macaque-derived
cDNA (data not shown) prior to performing the quanti-
tative assays. The same was done for the housekeeping
gene chosen, RNA polymerase II (RPII). The primers for
HERV-E4-1 have been successfully applied to barbary
macaques [40]. Using QPCR we could confirm a
significantly elevated HERV-E4-1 expression in the BSE-
infected animals as compared to the non-infected con-
trols in the basis pontis (Figure 3A) as well as in the ver-
mis cerebelli (Figure 3B). In addition HERV-K-(HML-3)
and the macaque-specific ERV MacERV-4 showed a
statistically significant increase in expression upon BSE-
infection in both tested brain regions. Since the control
animals were not mock infected we cannot rule out that
expression of endogenous retroviruses was influenced by
the inoculation procedure itself. However, the regions
used for our study were spatially separated from the site
of inoculation. In addition, our expression analysis was
performed approximately 3 years post inoculation which
virtually excludes persistent effects triggered by injection
of tissue homogenate. In summary, we have identified
and validated three ERVs that exhibit an increased
expression upon BSE-infection of cynomolgus macaques
using two independent techniques, microarray and
Figure 2 Microarray analysis of ERV-expression in BSE-infected compared to non-infected macaques. Fluorescence signal intensities from
six BSE-infected macaques were compared to four non-infected controls. Relative expression was calculated as the ratio to the expression of the
housekeeping gene HPRT. Results for ERV-E4-1, MacERV-4 and ERV-9 group members Seq60, ERV-9 and Seq59 are shown for basis pontis (A) and
vermis cerebelli (B). Statistical significance was analysed using the unpaired students t-test (** p < 0.01; * p < 0.05; ns, not significant). (C) shows
non-regulated HERV-L (Seq45) in both brain regions.
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exhibited comparable levels in both of the investigated
regions, basis pontis and vermis cerebelli.
Comparison of ERV-K-(HML-2) Gag protein levels in the
frontal/parietal cortex from BSE-infected and
non-infected macaques
Only a few antibodies against ERVs are commercially
available. Even fewer have been tested against
non-human primates. Unfortunately, to our knowledge,
antibodies directed against polypeptides encoded by the
BSE-induced ERVs HERV-E4-1, HERV-K-(HML-3),
ERV-9 and MacERV-4 do not exist. We tested a panel
of ERV-antibodies (kindly provided by J. Mayer) against
Homo sapiens ERV-K-(HML-2) Gag and Env for cross-
reactivity with macaque ERV-K-(HML-2) proteins in
cortical samples from Macaca fascicularis.M o s to ft h e
tested antibodies showed low specificity (K1182, polyclo-
nal) or no signal (monoclonal antibodies 6E2-1-4, 3H11
and HERM-1831-5) (data not shown). However, polyclo-
nal antibody K2548 that has been raised against HERV-
K-(HML-2) Gag [45] exhibited specific bands (Figure 4).
Proteins at 70, 80 and 105 kDa, respectively, showed an
identical migration pattern in simian brain as compared
to a human brain sample. Furthermore, the band at 80
kDa coincides with the 80 kDa full-length Gag protein
that is secreted from teratocarcinoma cells (Tera-1) cells
[47]. Both, incubation with secondary antibody alone
Figure 3 Relative quantification of ERV-expression in BSE-infected versus non-infected macaques using QPCR. Quantitative expression of
ERV-E4-1 and MacERV-4 were assessed by QPCR. Expression was normalized to the housekeeping gene RPII. Points represent the mean of two
experiments in duplicates is shown. Statistical significance was determined by unpaired students t-test (*** p < 0.001; ** p < 0.01; * p < 0.05).
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any signal in the respective molecular weight range,
confirming that the K2548 antiserum specifically detects
macaque ERV-K-(HML-2) Gag. Using this panel of posi-
tive and negative controls we concluded that antiserum
K2548 could specifically detect macaque ERV-K-
(HML-2) Gag. It should be mentioned that the probes
a n da n t i s e r au s e di no u rs t u d yw e r en o td e v e l o p e df o r
the use in cynomolgus macaques. However, macaques
and humans are very closely related species on the DNA
and on the protein level. In addition, we have demon-
strated that the used antiserum detects the same pro-
teins in human and Macaca fascicularis brain samples.
This suggests that the cross-reactivity is sufficient to
support our conclusions.
We next addressed the question whether macaque
ERV-K-(HML-2) Gag protein was differentially
expressed in BSE-infected compared to non-infected
macaques. Western blot analysis revealed a considerably
lower abundance of macaque ERV-K-(HML-2) Gag in
the prion-infected animals (Figure 5A). To quantify the
difference in the protein levels we performed a densito-
metric analysis. Normalization to the co-detected
beta-actin revealed that macaque ERV-K-(HML-2) Gag
protein expression was significantly decreased in BSE-
infected macaques as comparedt on o n - i n f e c t e di n d i v i -
duals (Figure 5B). This reduction was confirmed in
three independent Western blot experiments and by
densitometric analysis of total protein staining using
Ponceau S (data not shown).
To analyse whether the downregulation was mirrored
at the RNA-level we performed a macaque ERV-K-
(HML-2) gag specific QPCR on RNA samples derived
from the frontal/parietal cortex. A significant downregu-
lation of ERV-K-(HML-2) RNA expression was observed
in infected animals, which is consistent with the protein
expression data for this brain region (Figure 5C). To our
knowledge this is the first report of the regulation of an
endogenous virus protein coinciding with prion disease
in cynomolgus macaques as a model for Creutzfeldt-
Jacob disease.
Discussion
Although regarded as a part of the “Junk DNA”,E R V s
have been shown to play unique functional roles in cellu-
lar biology and are implicated in a wide range of diseases
like cancer, autoimmune disease, and neurodegeneration
[48-51]. We first compared the expression profiles of our
old world monkeys (Macaca fascicularis)t oe x i s t i n g
human profiles [41,46,52]. Beside a broad number of
similarities, we identified differences in the expression
profiles between humans and macaques when comparing
Class II betaretroviruses. The HERV-K-(HML-2, -6,
and -9) that are strongly expressed in human brain are at
the detection limit in macaque brain.
This result is consistent with prior studies of Old
World Monkey ERV expression in brain compared to
h u m a nu s i n gac o m p a r a b l em i c r o a r r a ya n dQ P C R[ 4 0 ] .
In addition, HERV-K-(HML-3) is more strongly
expressed in the basis pontis as compared to the vermis
cerebelli of cynomolgus macaque brain. This shows that
regional specific differences in ERV expression for class
II beta-retroviruses exist in macaques arguing for a
functional relevance of these transcripts. We cannot
judge whether this finding depicts a general phenom-
enon. However, the brain region specific expression of
ERVs may provide additional insights into molecular
mechanisms regulated by ERVs.
Using our non-human primate model we next exam-
ined the regulation of endogenous retrovirus expression
upon BSE-infection. To date, prion-infected macaques
have not been used for analysis of ERV-expression. Dif-
ferential expression of ERVs upon prion disease have
been previously reported in other species, including
humans, though brain material has not been examined
[28]. Here we provide evidence that ERVs are differen-
tially expressed in an experimentally controlled macaque
model of BSE-infection which is highly relevant for
human CJD. We have identified the upregulation of
ERVs E4-1, MacERV-4, and ERV-9 by ERV-specific
microarray. Interestingly, ERV-9 has also been shown to
Figure 4 Specific detection of ERV-K-(HML-2) Gag in brain
samples derived from macaques and humans. Extracts from the
frontal/parietal cortex region of M. fascicularis and H. sapiens,
respectively, and lysates from Tera-1 cells (kindly provided by Dr. J.
Mayer) were separated by PAGE and blotted to PVDF membrane.
Detection was performed with polyclonal antibody K2548 (left
panel), pre-immune serum (middle) or by omission of the primary
antibody (right panel), respectively. Predominant HERV-K-(HML-2)
Gag immunoreactivity was detected at 70, 80 and 105 kDa, but was
absent in the pre-immune and secondary antibody controls.
Molecular weight marker bands are indicated at the right.
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[28]. Thus, the macaque-adapted BSE and human sCJD
profiles show common ERV-regulation patterns in
response to prion infection irrespective of the analysed
sample types (brain or cerebrospinal fluid).
We could not judge whether the regulation of ERVs is
cause or consequence of prion infection. Although many
in vivo studies have been performed, the mechanism con-
necting prion deposition and neuronal loss has not been
determined in detail. The spatial distribution of PrP
Sc-
aggregates in different brain regions is not always coinci-
dent with neuronal decay in these areas. Thus it appears
that neurodegeneration itself could be promoted by bio-
logical pathways that are more complex than protein
aggregation, possibly by analogous mechanisms as
described for neurotropic retroviruses. Indeed, it is
known that some retroviruses can induce neurodegenera-
tion in the absence of infectious prions. Different classes
of leukemia retroviruses, including CasBrE, 10A1-MuLV,
ts1MoMuLV-TB and MoAmphoV induce fatal spongi-
form encephalomyelopathy [35-37]. Symptoms include
tremor, wasting and paraparesis that is caused by neuro-
nal loss, spongiform lesions and astrogliosis, which is
intriguingly similar to prion disease pathology [53]. All
four retroviruses are classified as gammaretroviruses, the
same subgroup as the here described BSE-upregulated
MacERV-4, ERV-9 and HERV-E. Thus, changes in ERV
expression may induce or exacerbate the pathological
consequences of neurodegeneration.
Upregulation of endogenous retroviruses can also
potentially induce neurodegeneration. It has been shown
that the regulatory LTR-region of HERV-E regulates the
expression of the Opitz-syndrome associated mid1 gene
[54] that is essential for vermis cerebelli development
[55]. It has been proposed that overexpression of mid1
leads to disturbance in microtubule-homeostasis,
Figure 5 Reduced expression of macaque ERV-K-(HML-2) Gag in brains of BSE-infected macaques. (A). Extracts derived from the frontal/
parietal cortex of BSE-infected (right) or non-infected (left) of Macaca fascicularis were subjected to PAGE, blotted to PVDF membrane and
incubated with K2548. Immunoreactivity was visualized with NBT/BCIP. For loading control the blot was co-incubated with a monoclonal beta-
actin antibody. (B). Densitometric analysis of A. NBT/BCIP-intensities of HERV-K-(HML-2) Gag were normalized to beta-actin intensities. Statistical
analysis was performed using the unpaired students t-test (* p < 0.05). (C) Quantitative expression of ERV-K-(HML-2) assessed by QPCR.
Expression was normalized to the housekeeping gene RPII. Points represent the mean of two experiments in duplicates. Statistical significance
was determined by unpaired t-test (* p < 0.05).
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loss in Alzheimer’s disease [56,57]. Thus upregulation of
HERV-E in BSE-infected macaques may also contribute
to neuronal decay similar to the above mechanism. This
suggests that induction of retroviral elements may be a
consequence of prion infection, and a downstream
mechanism of neurodegeneration [36]. This, however,
does not imply that endogenous retroviruses can cause
prion disease. The appearance of viral particles in prion-
infected cells [58,59] has been discussed controversially.
Interestingly, recent work has identified PrP
C as an inte-
gral component of the Human Immunodeficiency Virus-
1 (HIV-1) [60]. After cells are infected with HIV-1, the
virus replicates, assembles and buds preferentially from
the lipid rafts [61] presumably including the GPI-
anchored PrP
C into the surface of the HIV-1 particles.
In addition, HIV-1 Gag and Env colocalize with PrP
C in
infected T-cell lines [62]. Furthermore, expression of
HIV-1 gag increases the susceptibility to and sustains
the prion infection in cell culture [26,63]. Thus spread-
ing of prion infection from one cell to another may not
be restricted to exosomal vesicle transfer [64], but may
also be triggered by Gag of endogenous origin, such as
MacERV-K-(HML-2) Gag. In line with this, murine N2a
cells express, produce, and release MuLV (murine-leu-
kaemia virus) particles of endogenous origin, called
NeRV (neuroblastoma endogenous retrovirus) [65].
Infection of N2a cells with prions leads to the excretion
of exosomes that harbor PrP
C or infectious PrP
Sc. Intri-
guingly, antibodies against PrP
C could label both, exo-
somes and infectious virions [66]. This suggests that
intercellular trafficking of prions could at least partially
be mediated by hitchhiking on endogenous retroviral
particles. This is in line with earlier observations that
PrP can interact with retroviral RNA [67-69] eventually
resulting in the formation of active nucleoprotein struc-
tures [70] that include Gag. Using specific antibodies we
could show that macERV-K-(HML-2) Gag protein is
expressed in the brains of cynomolgus macaques. To
our knowledge this is the first time that a structural ele-
ment of an endogenous retrovirus has been detected in
the primate central nervous system. The functional role
of the protein in neuronal physiology is unknown. Inter-
estingly, among the many endogenous retroviral subfa-
milies, HERV-K-(HML-2) can produce viral particles
[71-74]. It remains unclear whether macERV (HML-2)
Gag can be excreted by neurons. However, active release
of HERV-K-(HML-2) Gag containing retrovirus-like par-
ticles have been described in Tera-1 [47] cells and were
also found in blood plasma of patients [75,76]. Taken
together, the detection of macERV-K-(HML-2) protein
in the frontal/parietal cortex indicates that it may have
a physiological role in the brain. Furthermore, finding
that HERV-K-(HML-2) Gag protein and RNA is
downregulated in BSE-infected macaques suggests that
this role may be connected to neuronal survival. Further
studies will be necessary to determine the mechanism
and function of HERV-K HML-2 Gag downregulation.
Conclusions
We could show that prion disease in a non-human
primate model is associated with the alteration of ERV-
expression at the transcriptional and the protein level.
Upregulated expression of ERVs in macaques demon-
s t r a t e dp a r t i a lo v e r l a pt ot h o s ef o u n di nC S Ff r o m
human CJD patients, underlining that our model is
especially suitable to mimic the pathology of human
TSEs. This is consistent with the hypothesis that endo-
genous retroviruses may provide a missing link between
protein aggregation and neuronal loss in prion diseases.
It is reasonable to speculate that the putatively secreted
HERV-K (HML-2) Gag may contribute to the survival
of neuronal cells.
Based on our findings, further research using specia-
lized models may help to elucidate the association
between prions and endogenous retroviruses and its
putative role in neurodegeneration.
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